Immunosuppression in Peripheral Neuropathy: Rationale and Reality

IJ Sutton; John Winer

doi:10.1016/S1471-4892(02)00158-3

Immunosuppression in Peripheral Neuropathy: Rationale and Reality

IJ Sutton
, John Winer

Birmingham Medical School

Research output: Contribution to journal › Article

4 Citations (Scopus)

Abstract

Plasma exchange, intravenous immunoglobulin and corticosteroids continue to be the mainstay of treatment for inflammatory neuropathies. Recent trials demonstrate that combining these therapies is not significantly more effective than single agent treatment. The usefulness of novel immunotherapies and cytotoxic agents is difficult to ascertain because of the treatment of small numbers of patients in open-label studies.

Original language	English
Pages (from-to)	291-295
Number of pages	5
Journal	Current Opinion in Pharmacology
Volume	2
Issue number	3
DOIs	https://doi.org/10.1016/S1471-4892(02)00158-3
Publication status	Published - 1 Jun 2002

Access to Document

10.1016/S1471-4892(02)00158-3

Cite this

@article{86345f4963f147a8a5f715b778d4e042,

title = "Immunosuppression in Peripheral Neuropathy: Rationale and Reality",

abstract = "Plasma exchange, intravenous immunoglobulin and corticosteroids continue to be the mainstay of treatment for inflammatory neuropathies. Recent trials demonstrate that combining these therapies is not significantly more effective than single agent treatment. The usefulness of novel immunotherapies and cytotoxic agents is difficult to ascertain because of the treatment of small numbers of patients in open-label studies.",

author = "IJ Sutton and John Winer",

year = "2002",

month = jun,

day = "1",

doi = "10.1016/S1471-4892(02)00158-3",

language = "English",

volume = "2",

pages = "291--295",

journal = "Current Opinion in Pharmacology",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Immunosuppression in Peripheral Neuropathy: Rationale and Reality

AU - Sutton, IJ

AU - Winer, John

PY - 2002/6/1

Y1 - 2002/6/1

N2 - Plasma exchange, intravenous immunoglobulin and corticosteroids continue to be the mainstay of treatment for inflammatory neuropathies. Recent trials demonstrate that combining these therapies is not significantly more effective than single agent treatment. The usefulness of novel immunotherapies and cytotoxic agents is difficult to ascertain because of the treatment of small numbers of patients in open-label studies.

AB - Plasma exchange, intravenous immunoglobulin and corticosteroids continue to be the mainstay of treatment for inflammatory neuropathies. Recent trials demonstrate that combining these therapies is not significantly more effective than single agent treatment. The usefulness of novel immunotherapies and cytotoxic agents is difficult to ascertain because of the treatment of small numbers of patients in open-label studies.

UR - https://www.scopus.com/pages/publications/0036605673

U2 - 10.1016/S1471-4892(02)00158-3

DO - 10.1016/S1471-4892(02)00158-3

M3 - Article

C2 - 12020473

VL - 2

SP - 291

EP - 295

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

IS - 3

ER -

Immunosuppression in Peripheral Neuropathy: Rationale and Reality

Abstract

Access to Document

Fingerprint

Cite this